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Abstract
Peritonitis caused by Staphylococcus aureus is a serious complication of peritoneal dialysis (PD), which is associated with
poor outcome and high PD failure rates. We reviewed the records of 62 S. aureus peritonitis episodes that occurred between
1996 and 2010 in the dialysis unit of a single university hospital and evaluated the host and bacterial factors influencing
peritonitis outcome. Peritonitis incidence was calculated for three subsequent 5-year periods and compared using a Poisson
regression model. The production of biofilm, enzymes, and toxins was evaluated. Oxacillin resistance was evaluated based
on minimum inhibitory concentration and presence of the mecA gene. Logistic regression was used for the analysis of
demographic, clinical, and microbiological factors influencing peritonitis outcome. Resolution and death rates were
compared with 117 contemporary coagulase-negative staphylococcus (CoNS) episodes. The incidence of S. aureus
peritonitis declined significantly over time from 0.13 in 1996–2000 to 0.04 episodes/patient/year in 2006–2010 (p=0.03).
The oxacillin resistance rate was 11.3%. Toxin and enzyme production was expressive, except for enterotoxin D. Biofilm
production was positive in 88.7% of strains. The presence of the mecA gene was associated with a higher frequency of fever
and abdominal pain. The logistic regression model showed that diabetes mellitus (p=0.009) and b-hemolysin production
(p=0.006) were independent predictors of non-resolution of infection. The probability of resolution was higher among
patients aged 41 to 60 years than among those .60 years (p=0.02). A trend to higher death rate was observed for S. aureus
episodes (9.7%) compared to CoNS episodes (2.5%), (p=0.08), whereas resolution rates were similar. Despite the decline in
incidence, S. aureus peritonitis remains a serious complication of PD that is associated with a high death rate. The outcome
of this infection is negatively influenced by host factors such as age and diabetes mellitus. In addition, b-hemolysin
production is predictive of non-resolution of infection, suggesting a pathogenic role of this factor in PD-related S. aureus
peritonitis.
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Introduction
Peritonitis is a serious complication of peritoneal dialysis (PD)
and is responsible for a high rate of technique failure and death in
PD patients [1]. Gram-positive cocci are the main etiological
agents of peritonitis in the world, with coagulase-negative
staphylococci (CoNS) being the most common microbial agents,
whereas Staphylococcus aureus is associated with more severe
episodes, a higher risk of hospitalization, catheter removal, and
death [1,2]. Although S. aureus is responsible for a small proportion
of peritonitis episodes in most countries, it continues to be the
leading cause of this infection in some Latin American countries,
particularly in Brazil [3].
A poor prognosis of PD-related S. aureus peritonitis has been
frequently reported [2,4,5], but there are only two reports [6,7]
that specifically describe the clinical outcome and predictors of
treatment response in this infection. In the largest series,
Govindarajulu et al. [6] showed that methicillin-resistant S. aureus
(MRSA) peritonitis was independently predictive of an increased
risk of permanent hemodialysis transfer and tended to be
associated with a high risk of hospitalization. Szeto et al. [7]
reported a lower primary response rate and complete cure rate for
episodes caused by MRSA compared to episodes due to other S.
aureus. In both cases the clinical outcome of S. aureus peritonitis was
not encouraging. The rates of relapse, catheter removal and
hospitalization were 20%, 23% and 67%, respectively, in the study
of Govindarajulu et al. [6]. In the series of Szeto et al. [7], only
51% of patients with methicillin-susceptible S. aureus peritonitis
and 46% with MRSA peritonitis presented complete cure without
relapse, recurrent or repeat episodes, or need for catheter removal.
In addition to antibiotic resistance, the severity of S. aureus
infections is associated with virulence factors produced by this
bacterium, such as enzymes (coagulase, lipase, and nucleases) and
multiple toxins with diverse activities. One family of protein toxins
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syndrome toxin-1 (TSST-1) that act as superantigens [8]. The
biofilm produced by most S. aureus strains facilitates bacterial
adhesion to catheters and colonization and simultaneously worsens
the response to infection, protecting bacterial cells from the host’s
natural defense mechanisms and from the action of antibiotics
[8,9]. Although these products may influence clinical outcome,
their role in PD-related S. aureus peritonitis is still not fully defined.
Data published by Haslinger-Lo ¨ffler et al. [10] suggest that a-
hemolysin plays a specific role in the pathogenesis of peritonitis.
Using cultured human peritoneal mesothelial cells, these authors
showed that a-hemolysin produced by S. aureus was able to induce
caspase-independent cell death. In a recent study, our group
demonstrated that biofilm and a-hemolysin production were the
only independent predictors of non-resolution of staphylococcal
peritonitis [11]. However, the small number of S. aureus episodes
analyzed was an important limitation of that study.
For the last 15 years we have monitored clinical and
microbiological characteristics of S. aureus peritonitis in PD
patients, including virulence factors produced by this pathogen
and presence of the mecA gene that confers resistance to
methicillin/oxacillin. The objective of the present study was to
describe the experience of a single Brazilian center with PD-
related S. aureus peritonitis, focusing on host and bacterial factors
that influence peritonitis outcome.
Results
A total of 682 peritonitis episodes were diagnosed in our unit
between 1996 and 2010. The overall peritonitis rate was 0.96
episodes per patient per year. Seventy-three (10.7%) episodes were
caused by S. aureus. After application of the exclusion criteria, 62
episodes that occurred in 56 patients were analyzed. The
demographic and baseline clinical data of the patients are
summarized in Table 1. The clinical findings in peritonitis
episodes were expressed in Table 2. The incidence of S. aureus
peritonitis declined significantly over time and was 0.13 episodes
per patient per year in 1996–2000, 0.10 in 2001–2005, and 0.04 in
2006–2010 (p=0.03). The annual S. aureus peritonitis rate is
presented in figure 1; a strong decline of the incidence was
observed after 2003. Vancomycin was used in 35 (56.5%) episodes.
Overall, 32 (51.6%) episodes were resolved; among cases that were
not resolved one (0.16%) relapsed, 18 (29%) required removal of
the catheter due to refractory peritonitis, five (8%) were resolved
with a second antibiotic regimen, and six (9.7%) progressed to
death. Of 117 contemporary CoNS peritonitis episodes, 63
(53.8%) were resolved and three (2.5%) progressed to death.
The death rate tended to be lower among episodes caused by
CoNS than among S. aureus episodes (p=0.08), whereas resolution
rates were similar (p=0.16).
All strains were susceptible to vancomycin (MIC#3 mg/ml) and
seven (11.3%) were resistant to oxacillin (MIC$4 mg/ml). The
vancomycin MIC or proportion of oxacillin-resistant isolates did
not change significantly over time (Figure 2). The mecA gene was
detected in seven (11.3%) strains.
The rates of toxin and enzyme production by S. aureus are
shown in Table 3. No associations were observed between the
production of virulence factors and the frequency of initial clinical
findings. However, fever was observed in 83.3% of episodes
caused by bacteria expressing the mecA gene, whereas this clinical
symptom was present in only 24% of episodes due to mecA gene-
negative strains (p=0.03). In addition, there was a trend towards a
higher rate of abdominal pain (100%) among strains expressing
the mecA gene compared to mecA gene-negative isolates (64.8%)
(p=0.08). The production of virulence factors and presence of the
mecA gene were not associated with catheter removal, hospitaliza-
tion, or death rate.
Gender, age, vancomycin use, presence of diabetes, production
of virulence factors (b-hemolysin, lecithinase, deoxyribonuclease,
SEC, and TSST-1), presence of the mecA gene, and dialysis vintage
were associated with a higher chance of non-resolution in
univariate analysis (Table 4), and were therefore included in the
multivariate logistic regression model. Multivariate analysis
showed that the presence of diabetes and b-hemolysin production
were factors independently associated with a higher odds ratio of
non-resolution of peritonitis episodes. In contrast, age of 41–60
years was associated with a lower chance of non-resolution when
compared to age .60 years. No significant association with
peritonitis outcome was observed for the other variables (Table 4).
Discussion
The present results showed a marked decline in the incidence
and proportion of peritonitis episodes caused by S. aureus over the
past 15 years, in agreement with other studies [3,12]. The
introduction of safer connection systems and the routine use of
Table 1. Summary of Patient Characteristics at Baseline
(n=56).
Frequency %
Age (years)
#20 4 7.2
21–40 12 21.4
41–60 20 35.7
.60 20 35.7
Male gender 23 41.1
Presence of diabetes 28 50
Educational Level
Elementary 30 53.6
Secondary 8 14.3
Higher 6 10.7
Illiterate 7 12.5
Unknown 5 8.9
PD modality
APD 9 16.6
CAPD 47 83.3
PD, peritoneal dialysis; APD, automated peritoneal dialysis; CAPD, continuous
ambulatory peritoneal dialysis.
doi:10.1371/journal.pone.0031780.t001
Table 2. Clinical findings in S. aureus peritonitis episodes.
Sign or symptom N %
Cloudy Dialysis Effluent 60 96.8
Abdominal pain 42 67.7
Nausea or vomiting 26 41.9
Fever 18 29.0
Hypotension 12 19.3
doi:10.1371/journal.pone.0031780.t002
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uted to the reduction of the incidence of S. aureus peritonitis;
however the strong decline in the incidence observed after the
introduction of the prophylaxis with mupirocin reinforces the role
of this strategy on S. aureus peritonitis prevention. In addition, in
the present series we observed a higher death rate among S. aureus
episodes compared to episodes caused by CoNS as previously
reported [1].
There are few studies reporting the influence of demographic
and clinical factors on the prognosis of S. aureus peritonitis
episodes. Szeto et al. [7] observed an association between adjuvant
rifampicin treatment and a significantly lower risk of relapse,
whereas the complete cure rate was similar for cephalosporin and
vancomycin empiric treatment protocols. Govindarajulu et al. [6]
found that the presence of peripheral vascular disease and the use
of vancomycin compared to cephalosporins were significantly
associated with an increased risk of relapse of S. aureus peritonitis.
According to these authors, female gender and middle tertile of
age were independent predictors of a lower risk of relapse.
Similarly, we observed that patient age of 41 to 60 years was
associated with a higher chance of peritonitis resolution when
compared to older patients. In addition, the presence of diabetes
was an independent predictor of non-resolution of peritonitis. It is
known that the immune response is dysregulated in diabetic
Figure 1. Annual Rate (episodes/patient/year) of Staphylococcus aureus Peritonitis from January 1996 to December 2010.
doi:10.1371/journal.pone.0031780.g001
Figure 2. Vancomycin Minimum Inhibitory Concentration (MIC50) and Proportion of Oxacillin-Resistant Staphylococcus aureus
Strains Isolated from Peritoneal Dialysis Patients with Peritonitis between 1996 and 2010.
doi:10.1371/journal.pone.0031780.g002
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advanced glycation end-products act on peritoneal mesothelial
cells, with a potentially negative impact on the local immune
response [13]. Although diabetes has been reported to be a risk
factor for peritonitis [14], to our knowledge, there are no studies
showing diabetes to be a predictor of poor outcome after a
peritonitis episode. In the present series, vancomycin use was not
an independent predictor of outcome, in agreement with the study
of Szeto et al. [7]. We observed no influence of other demographic
or clinical factors on resolution rate. Similar results have been
reported by Krishnan et al. [15] in a retrospective series of
peritonitis episodes of different causes.
Little is known about the influence of specific virulence factors
on peritonitis caused by S. aureus. MRSA peritonitis has been
associated with poor outcome in the two largest series of S. aureus
peritonitis [6,7]. In the present series, we found a low oxacillin
resistance rate, which was confirmed by determination of the mecA
gene. On the other hand, the S. aureus strains studied presented
expressive enzyme, toxin, and biofilm production. In contrast to
previous studies we found no association between oxacillin
resistance and resolution rate; however, in the present series only
seven peritonitis episodes were caused by oxacillin-resistant S.
aureus, a fact that may have influenced the results. Episodes caused
by mecA-positive S. aureus isolates were associated with more severe
initial clinical symptoms. Studies investigating the role of the mecA
gene in the virulence of S. aureus are scarce in the literature. Fowler
Jr et al. [16] found an increasing proportion of MRSA among
strains isolated from nasal carriage, uncomplicated bacteremia,
and bacteremia with hematogenous complications. Analyzing the
same sample later, Gill et al. [17] confirmed a higher frequency of
the mecA gene among S. aureus strains isolated from severe
infections. In our laboratory [18] analyzing 336 MRSA and 107
MSSA strains, we observed a significantly higher proportion of
strains expressing SEA, SEB, SEC and TSST-1 genes among
MRSA. Taken together, these findings show that, although the
number of strains expressing the mecA gene was small in this series,
a role of the mecA gene in S. aureus virulence cannot be ruled out.
Among bacterial factors studied, b-hemolysin production was
significantly and independently associated with lower resolution
odds. The role of b-hemolysin in the pathogenesis of S. aureus
infections has not been previously reported in PD-related
peritonitis. Nevertheless, some pathways may be suggested based
on the findings of experimental models. b-Hemolysin is one of the
toxins produced by S. aureus which acts as a sphingomyelinase,
degrading sphingomyelin in the outer layer of cell membranes
[19]. Deletion of the catalase and b-toxin genes in S. aureus strains
has been shown to cause strong attenuation of virulence in
intramammary and subcutaneous experimental infections of ewes
and lambs and in a murine skin abscess model [19]. Using a mouse
model of lung injury, Hayashida et al. [20] found that animals
infected with b-hemolysin-deficient S. aureus presented significantly
attenuated lesions compared to those infected with S. aureus
expressing this toxin. This experimental disease was characterized
by intense neutrophilic inflammation and reduced expression of
syndecan-1 in alveolar epithelial cells and could be reproduced by
administration of recombinant b-hemolysin, but not of mutant b-
hemolysin deficient in sphingomyelinase activity.
Extracellular DNA is a major structural component in the
biofilms of pathogenic S. aureus. Huseby et al. [21] showed that b-
hemolysin forms covalent cross-links to itself in the presence of
DNA, irrespective of sphingomyelinase activity, producing an
insoluble nucleoprotein matrix in vitro. Using an infectious
endocarditis rabbit model, the authors observed that this toxin
stimulates biofilm formation in vivo. b-Hemolysin does not lyse
most types of host cells but leaves them vulnerable to a number of
other lytic agents, such as a-hemolysin and Panton-Valentine
leukocidin [20]. We recently demonstrated that a-hemolysin
production predicts poor outcome in peritonitis episodes caused by
S. aureus and CoNS [11].
A reservoir of phospholipids exists on the peritoneal surface and
the main constituents of peritoneal phospholipids are phosphati-
dylcholine and sphingomyelin [22]. Indeed, evidence suggests that
the phospholipids present on the peritoneal surface are derived
from peritoneal mesothelial cells. In this respect, b-hemolysin, a
sphingomyelinase, may participate directly in biofilm formation,
contributing to a poorer outcome of peritonitis episodes, or may
render host peritoneal cells susceptible to other pathogenic factors.
Surprisingly, biofilm production was not a predictor of
peritonitis resolution. However, the percentages of non-producers
was low, a fact impairing the comparison with biofilm producers;
therefore, a role of biofilm production in peritonitis outcome
cannot be ruled out. Finally, other S. aureus virulence factors that
act in a synergistic and coordinated fashion may play a pathogenic
role.
The present study has several limitations, the most important of
them is the absence of more accurate tests to assess production of
b-hemolysin such as mRNA levels using quantitative real time-
PCR or specific detection such as by ELISA or Western Blot. Also,
the small number of cases analyzed that may reduce its statistical
power, and since it is a single-center study its results cannot be
extrapolated. Nevertheless, it is the first Latin American study
analyzing a series of S. aureus peritonitis cases. In this respect, S.
aureus remains the most frequent PD-related etiology in several
Latin American countries, including Brazil [3]. Furthermore, this
study focused on the role of virulence factors on the outcome of
this infection.
In conclusion, despite a strong reduction in the incidence of S.
aureus peritonitis, our results showed a poorer outcome of episodes
caused by this bacterium when compared to episodes due to
CoNS, particularly a higher death rate. Among demographic
factors, older age and diabetes were predictors of a lower
resolution rate. These findings highlight the importance of
peritonitis as a serious complication of PD, particularly among
Table 3. Production Rates of Pathogenic Factors by S. aureus
strains Isolated from 62 Peritonitis Episodes.
N%
Enzymes
a-Hemolysin 27 43.5
b-Hemolysin 24 38.7
Lipase 52 83.9
Lecithinase 57 91.9
Deoxyribonuclease 58 93.5
Thermonuclease 56 90.3
Toxins
SEA 7 11.3
SEB 17 27.4
SEC 12 19.4
TSST-1 17 27.4
Biofilm 55 88.7
SEA, SEB, SEC, enterotoxins A, B and C, respectively; TSST-1, toxic shock
syndrome toxin-1.
doi:10.1371/journal.pone.0031780.t003
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only virulence factor that negatively influenced peritonitis
outcome; however further studies using specific tests to detect
the presence of b-hemolysin are necessary to confirm this result.
Materials and Methods
All episodes of ambulatory PD-related peritonitis caused by
Staphylococcus aureusbetween January 1996andDecember2010 were
reviewed. The diagnosis of peritonitis was made when at least two of
the following criteria were present: 1) presence of a cloudy
peritoneal effluent; 2) abdominal pain; 3) dialysate containing more
than 100 white blood cells per ml (at least 50% polymorphonuclear
cells),and4)positivecultureofperitonealeffluent[23,24].Exclusion
criteria were episodes of relapsing S. aureus peritonitis, presence of
concomitant exit site or tunnel infections, and incomplete clinical
data. Resolution was defined as the disappearance of signs and
symptoms within 96 h after the beginning of antibiotic therapy and
a negative peritoneal fluid culture at least 28 days after treatment
completion [23,24]. Relapse was defined as an episode due to the
same organism, or a negative culture result that occurs within 28
days of completion of antibiotic therapy for a prior S. aureus episode
[23,24]. Death related to peritonitis was defined as death of a
patient with active peritonitis, or admitted with peritonitis, or within
2 weeks of a peritonitis episode [23,24]. Non-resolution was the
term used for cases presenting initial non-resolution, relapse,
peritoneal catheter removal due to refractory peritonitis, need for
a second antibiotic regimen, or death.
The following information was recorded for each case: 1)
episode: date, clinical findings, treatment, and outcome (resolu-
tion, relapse, catheter removal, or death); 2) presence of diabetes
mellitus; 3) demographic data: age, gender and race (Caucasian,
non-Caucasian), and dialysis treatment time; 4) dialysis modality
(continuous ambulatory peritoneal dialysis or automated perito-
neal dialysis); 5) educational level (illiterate, elementary, secondary,
and higher).
Table 4. Odds Comparison of Peritonitis Resolution by Logistic Regression Analysis.
Factor
p value
(univariate)
p value
(multivariate) OR 95% CI
Gender (female) 0.109 0.143 4.551 0.599–34.611
Caucasian race 0.642
Age (years) 0.042
#20 0.999 Exp(3.849) 0.000-
21–40 0.871 0.845 0.111–6.466
41–60 0.020 0.091 0.012–0.684
.60 (reference)
Educational level 0.934
Elementary
Secondary
Higher
Illiteracy
Vancomycin use 0.037 0.242 0.325 0.049–2.140
Presence of diabetes 0.042 0.009 14.682 1.960–112.676
Enzyme production
a-Hemolysin 0.632
b-Hemolysin 0.077 0.006 16.597 2.246–122.615
Lipase 0.204
Lecithinase 0.185 0.697 2.248 0.038–131.697
Deoxyribonuclease 0.033 0.999 Exp(6.296) 0.000-
Thermonuclease 0.934
Presence of mecA gene 0.195 0.838 1.430 0.046–44.342
Biofilm production 0.623
Toxin production
SEA 0.265
SEB 0.312
SEC 0.071 0.217 5.621 0.363–87.052
TSST-1 0.205 0.399 0.365 0.035–3.805
Dialysis vintage (months) 0.07 0.092 0.943 0.880–1.010
Dialysis modality
(APD vs CAPD)
0.477
SEA, SEB, SEC, enterotoxins A, B and C, respectively; TSST-1: toxic shock syndrome toxin-1; APD, automated peritoneal dialysis; CAPD, continuous ambulatory peritoneal
dialysis.
doi:10.1371/journal.pone.0031780.t004
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the Faculty of Medicine of Botucatu, Brazil (OF. 028/08-CEP).
This study was exempted from the requirement to obtain written
informed consent from the participants and/or their legal
guardians because the Staphylococcus strains included in the study
had already been isolated and stored in the Culture Collection of
the Department of Microbiology and Immunology, UNESP,
Botucatu, Sa ˜o Paulo, Brazil.
Patients were treated within 24 h of the onset of the first clinical
signs or symptoms using contemporary empiric antibiotic
recommendations [23–25]. From 1996 to 2000 (period 1) empiric
antibiotic therapy consisted of intraperitoneal (i.p.) cefazolin plus
amikacin. Two protocols were used from 2000 to 2005 (period 2):
the first consisted of i.p. cefazolin plus amikacin and the second of
i.p. cefazolin plus ceftazidime. After 2005 (period 3) all episodes
were first treated with i.p. vancomycin plus amikacin. Therapy
was evaluated and adjusted as soon as the culture results were
available. The duration of antibiotic therapy was 21 days.
In the period 1 no antibiotic prophylaxis at exit site was
prescribed and two connection systems were used: the Y set system
and the twin bag system, which was introduced in 1999;
automated PD (APD) was used from 1998. In the period 2 no
antibiotic prophylaxis at exit site was prescribed until 2003, when
daily mupirocin cream application at exit site began to be
recommended; the twin bag system or APD were prescribed for all
patients. In the period 3 until December 2006 all patients were
oriented to daily mupirocin cream application, and from January
2007 daily gentamicin cream application at exit site was prescribed
to all incident patients; the twin bag system or APD were
prescribed for all patients.
The incidence of S. aureus peritonitis was calculated for the three
subsequent periods of 5 years and is expressed as episodes per
patient per year.
The initial cultures were performed with the BactecH Automat-
ed System (Becton Dickinson Company, Sparks, Maryland, USA)
and then seeded onto blood agar. The isolates were Gram stained
to confirm purity and to determine morphology and specific color.
After confirmation of these characteristics, tests for identification
of the isolates were performed as recommended by Koneman et al.
[26]. The isolates were stored in a culture collection.
The in vitro susceptibility of S. aureus to oxacillin and
vancomycin was evaluated based on the minimum inhibitory
concentration determined by the E-test (AB Biodisk, Solna,
Sweden). This quantitative method uses a transparent strip of
inert plastic that contains drug concentrations ranging from 0.002
to 256 mg/ml. The proportion of strains susceptible to each drug
was defined based on the 2011 CLSI breakpoints [27]. Strains
presenting intermediate values were considered to be resistant.
Whole nucleic acids were extracted from S. aureus strains
cultured on blood agar, individually inoculated into brain heart
infusion (BHI) broth, and incubated at 37uC for 24 h. Nucleic
acids were extracted using the illustra blood genomic Prep Mini
Spin kit (GE Healthcare, Little Chalfont, Buckinghamshire, UK)
according to manufacturer instructions. Staphylococcal cells were
first digested with lysozyme (10 mg/ml) and proteinase K (20 mg/
ml). Next, 500 ml extraction solution was added to the mixture.
After centrifugation at 5000 g for 1 min, the supernatant was
transferred to a GFX column and centrifuged at 5000 g for 1 min.
The supernatant was discarded and 500 ml extraction solution was
added to the column. After centrifugation and disposal of the
supernatant, 500 ml wash solution was added to the column. The
column was then centrifuged at 14,000 rpm for 3 min and
transferred to a 1.5-ml tube. Milli-Q water (200 ml) preheated to
70uC was used for elution. The isolates were centrifuged at 5000 g
for 1 min and the GFX column was discarded. Extracted DNA
was stored under refrigeration at 4uC.
PCR amplification was performed in 0.5-ml microcentrifuge
tubes containing 10 pmol of each primer, 2.0 U Taq DNA
polymerase, 100 mM deoxyribonucleotide triphosphates, 10 mM
Tris-HCl (pH 8.4), 0.75 mM MgCl2, and 3 ml nucleic acid in a
total volume of 25 ml. Gene mecA amplification was carried out in
an appropriate thermal cycler using the mecA1 (AAA ATC GAT
GGT AAA GGT TGG) and mecA2 (AGT TCT GCA GTA
CCG GAT TTG) primers as described by Murakami et al. [28]:
40 cycles of denaturation at 94uC for 30 s, annealing of primers at
55.5uC for 30 s, and extension at 72uC for 1 min. After
completion of the 40 cycles, the tubes were incubated at 72uC
for 5 min and then cooled to 4uC. The S. aureus ATCC 33591 and
ATCC 25923 references strains were included in all reactions as
positive and negative controls, respectively.
The efficiency of amplification was monitored by electropho-
resis on 1.5% agarose gel prepared in 16TBE buffer and stained
with ethidium bromide. The size of the amplified products was
compared with a 100-bp standard and the gels were photographed
under UV transillumination.
Biofilm production was evaluated according to Christensen et
al. [29]. Colonies isolated on blood agar were inoculated into tubes
measuring 12.0675.0 mm and containing 2.0 ml trypticase soy
broth and incubated at 37uC for 48 h. Next, 1.0 ml 0.4% trypan
blue or Toluidine blue O solution was added to the tubes. After
gentle shaking to guarantee staining of the material adhered to the
inner surface of the tubes, the dye was discarded. A positive result
was defined as the presence of a layer of stained material adhered
to the inner wall of the tube. The presence of a colored ring only at
the liquid-air surface was classified as a negative result.
Production of a- and b-hemolysin were determined on plates
containing blood agar supplemented with 5% rabbit blood and
5% sheep blood, respectively. The plates were incubated at 37uC
for 24 h. The formation of hemolysis zones around the isolated
colonies indicated a positive result.
Lipolytic activity was evaluated on plates containing blood agar
enriched with 0.01% CaCl2:2H2O and 1% Tween 80. A positive
result was defined as the formation of opacity around the colony
after incubation at 37uC for 18 h, followed by incubation at room
temperature for 24 h [30]. The production of lecithinase was
evaluated using Baird-Parker medium. The formation of an
opaque halo around the colony indicated a positive result [31].
Nuclease (DNAse) and thermonuclease (TNAse) were deter-
mined by the metachromatic Toluidine blue O agar diffusion-
DNA technique according to Lachica et al. [32]. Supernatants
obtained by the sac culture method of Donnelly et al. [33] as
described below were transferred to the wells of plates containing
metachromatic Toluidine blue O agar. The culture supernatant
was first heated in a water bath for 20 min for the detection of
TNAse. Nuclease (DNAse and TNAse) activity was evaluated by
measuring the diameter of pink halos (mm) formed on the
medium. Positive results were interpreted by comparing the halos
with those obtained for a standard DNAse- and TNAse-positive S.
aureus strain (ATCC 25923).
For the evaluation of the production of enterotoxins and TSST-
1, the sac culture method [33] was used to determine the toxigenic
profile of the strains. Dialysis sacs filled with 50 ml double-
concentrated BHI broth were placed in U-shaped Erlenmeyer
flasks and autoclaved at 121uC for 15 min. A loopful of organisms
was added to 18 ml sterile 0.2 M phosphate buffer in 0.9% NaCl,
pH 7.4. After incubation at 37uC for 24 h on a shaker at 200 rpm,
the cultures were centrifuged at 8000 g for 10 min at 4uC and the
supernatants obtained were stored at 220uC until the time of use.
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agglutination (RPLA) using the SET-RPLA-T900 and TST-
RPLA-TD940 kits (Oxoid Diagnostic Reagents, Cambridge, UK)
for the detection of enterotoxins A (SEA), B (SEB), C (SEC) and D
(SED) and TSST-1, respectively, according to manufacturer
instructions. Samples that presented nonspecific reactions after
this treatment were filtered through a Millipore membrane
(0.22 mm) and, if necessary, diluted 1:10 with 0.02 M phosphate
buffer in 0.9% NaCl, pH 7.4. A positive reaction was classified as
(+), (++) and (+++) according to the agglutination pattern described
by the manufacturer of the kit. The formation of a rose button was
interpreted as a negative result.
Statistical analysis
Peritonitis incidences were compared using the Poisson
regression model. The association between microbiological
characteristics (oxacillin resistance, presence of mecA gene and
production of pathogenic factors) and the frequency of clinical
findings at initial presentation (abdominal pain, fever, nausea or
vomiting, and arterial hypotension) was analyzed by the chi-square
or Fisher’s exact test. These tests were also used to compare
resolution and death rates between S. aureus peritonitis episodes
and 117 contemporary CoNS cases. Multivariate analysis by
logistic regression was used to test baseline demographic, clinical,
and microbiological factors that independently predicted the
outcome of a peritonitis episode. Outcome was classified as two
mutually exhausted and exclusive results (resolution or non-
resolution). For this purpose, univariate analysis using the chi-
square or Fisher’s exact test (binary variables) or logistic regression
(continuous variables) was first performed to select the variables
that would enter the final model, with p.0.20 being used as an
elimination criterion. A p value less than 0.05 was considered to be
significant. All statistical analyses were performed using the SPSS
16.0 software (SPSSH, Inc.).
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